In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)
This article was originally published in PharmAsia News
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
You may also be interested in...
Sanofi Sees Strength In Regional Volatility, GSK Lowers Revenue Target After Price Cuts – Emerging Market Earnings Roundup (Part 4)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.
Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. In this feature, PharmAsia News takes a closer look.
Three years ago Sanofi didn’t know it was number one in emerging markets. Now the French pharma can’t talk enough about emerging markets – so what happened?